Iron Mountain Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Iron Mountain Inc trades at $113.5 (market cap $34.46B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.94B). The key difference: Iron Mountain Inc is far larger — about 8.7× Relay Therapeutics Inc. Common Stock's market cap, and Iron Mountain Inc pays a 2.99% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| IRM | RLAY | |
|---|---|---|
Market Cap | $34.46B | $3.94B |
Volume | 1,379,608 | 3,432,928 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $20.75 |
52-Week Low | $78.86 | $6.03 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $53.87B | $3.06B |
Dividend Yield | 2.99% | — |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $112.97, down 3.03% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent developments highlight expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus remains bullish with a $142.75 price target, representing 26% upside potential from current levels.
IRM presents a compelling growth story in data center expansion and digital transformation, but faces significant debt burden with 79% debt-to-asset ratio. While institutional ownership is growing and earnings consistently exceed expectations, high valuation multiples and declining profit margins warrant caution. The stock's near-term performance will depend on successful execution of digital initiatives and debt management.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →